Till sidans topp

Sidansvarig: Webbredaktion
Sidan uppdaterades: 2012-09-11 15:12

Tipsa en vän
Utskriftsversion

Can patch testing with me… - Göteborgs universitet Till startsida
Webbkarta
Till innehåll Läs mer om hur kakor används på gu.se

Can patch testing with methylchloroisothiazolinone/methylisothiazolinone be optimized using a new diagnostic mix? - A multicenter study from the Swedish Contact Dermatitis Research Group

Artikel i vetenskaplig tidskrift
Författare M. Engfeldt
M. Isaksson
Johanna Bråred Christensson
Lina Hagvall
M. Matura
K. Ryberg
B. Stenberg
C. Svedman
M. Bruze
Publicerad i Contact Dermatitis
Volym 82
Nummer/häfte 5
Sidor 283-289
ISSN 0105-1873
Publiceringsår 2020
Publicerad vid Institutionen för kliniska vetenskaper, Avdelningen för dermatologi och venereologi
Sidor 283-289
Språk en
Länkar dx.doi.org/10.1111/cod.13483
Ämnesord allergic contact dermatitis, contact sensitization, delayed, hypersensitivity, methylchloroisothiazolinone, methylisothiazolinone, (MCI, MI), mix, patch testing, active ingredients, european-society, 200 ppm, methylisothiazolinone, allergy, Allergy, Dermatology
Ämneskategorier Dermatologi och venereologi

Sammanfattning

Background Methylchloroisothiazolinone/methylisothiazolinone (MCI/MI) and methylisothiazolinone (MI) are tested to detect contact allergy to these isothiazolinones. Objectives To study if an aqueous patch test preparation with MCI and MI in a mix of 0.015% and 0.2%, respectively, detects more contact allergies than the commonly used preparations of MCI/MI in 0.02% aq. and MI in 0.2% aq. Methods A total of 1555 patients with dermatitis in five Swedish dermatology departments were tested consecutively with MCI/MI 0.215% aq., MCI/MI 0.02% aq., and MI 0.2% aq. Results The share of contact allergy to MCI/MI 0.215% aq., MCI/MI 0.02% aq., and MI 0.2% aq. varied in the test centers between 7.9% and 25.9%, 3.2% and 10.3%, and 5.8% and 12.3%, respectively. MCI/MI 0.215% aq. detected significantly more patch-test positive individuals than both MCI/MI 0.02% aq. (P < .001) and MI 0.2% aq. (P < .001), as well as either one of MCI/MI and MI (P < .001). In the patients only reacting to MCI/MI 0.215% aq., 57.7% were recorded as having a dermatitis that was explained or aggravated by exposure to either MCI/MI or MI. Conclusion The results speak in favor of replacing the preparations MCI/MI 0.02% aq. and MI 0.2% aq. with MCI/MI 0.215% aq. as the screening substance in the Swedish baseline series, which has been implemented in 2020.

Sidansvarig: Webbredaktion|Sidan uppdaterades: 2012-09-11
Dela:

På Göteborgs universitet använder vi kakor (cookies) för att webbplatsen ska fungera på ett bra sätt för dig. Genom att surfa vidare godkänner du att vi använder kakor.  Vad är kakor?